Literature DB >> 16738543

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

Robert M Kessler1, M Sib Ansari, Patrizia Riccardi, Rui Li, Karuna Jayathilake, Benoit Dawant, Herbert Y Meltzer.   

Abstract

Clozapine and quetiapine have a low incidence of extrapyramidal side effects at clinically effective doses, which appears to be related to their significantly lower occupancy of striatal dopamine D2 receptors (DA D2r) compared to typical antipsychotic drugs (APDs). Animal studies have indicated that clozapine and quetiapine produce selective effects on cortical and limbic regions of the brain and in particular on dopaminergic neurotransmission in these regions. Previous PET and SPECT studies have reported conflicting results regarding whether clozapine produces preferential occupancy of cortical DA D2r. To examine whether clozapine and/or quetiapine produce preferential occupancy of DA D2r in cortex and limbic regions, we studied the occupancy of putamenal, ventral striatal, thalamic, amygdala, substantia nigra, and temporal cortical DA D2r using PET with [18F]fallypride in six schizophrenic subjects receiving clozapine monotherapy and in seven schizophrenic subjects receiving quetiapine monotherapy. Doses were chosen clinically to minimize psychopathology at tolerable levels of side effects such as drowsiness. All had minimal positive symptoms at the time of the study. Regional receptor occupancies were estimated using mean regional DA D2r levels calculated for 10 off-medication schizophrenic subjects. Both clozapine and quetiapine produced lower levels of putamenal DA D2r occupancy than those reported for typical APDs, 47.8 and 33.5%, respectively. Clozapine produced preferential occupancy of temporal cortical vs putamenal DA D2r, 59.8% (p=0.05, corrected for multiple comparisons), and significantly lower levels of occupancy in the substantia nigra, 18.4% (p=0.0015, corrected for multiple comparisons). Quetiapine also produced preferential occupancy of temporal cortical DA D2r, 46.9% (p=0.03, corrected for multiple comparisons), but did not spare occupancy of substantia nigra DA D2r. The therapeutic effects of clozapine and quetiapine appear to be achieved at less than the 65% threshold for occupancy seen with typical APDs, consistent with the involvement of non-DA D2r mechanisms in at least partially mediating the therapeutic effects of these drugs. Preferential occupancy of cortical DA D2r, sparing occupancy of substantia nigra receptors, and non-DA D2r-mediated actions may contribute to the antipsychotic actions of these and other atypical APDs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738543     DOI: 10.1038/sj.npp.1301108

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

Review 1.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.

Authors:  Keisuke Takahata; Hiroshi Ito; Harumasa Takano; Ryosuke Arakawa; Hironobu Fujiwara; Yasuyuki Kimura; Fumitoshi Kodaka; Takeshi Sasaki; Tsuyoshi Nogami; Masayuki Suzuki; Tomohisa Nagashima; Hitoshi Shimada; Motoichiro Kato; Masaru Mimura; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2012-01-12       Impact factor: 4.530

3.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

4.  First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia.

Authors:  Kjetil N Jørgensen; Ragnar Nesvåg; Sindre Gunleiksrud; Andrea Raballo; Erik G Jönsson; Ingrid Agartz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-07       Impact factor: 5.270

Review 5.  The 'atypicality' of antipsychotics: a concept re-examined and re-defined.

Authors:  Gerhard Gründer; Hanns Hippius; Arvid Carlsson
Journal:  Nat Rev Drug Discov       Date:  2009-02-13       Impact factor: 84.694

Review 6.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.

Authors:  Robert E Davis; Kimberly E Vanover; Yun Zhou; James R Brašić; Maria Guevara; Blanca Bisuna; Weiguo Ye; Vanessa Raymont; William Willis; Anil Kumar; Lorena Gapasin; D Ronald Goldwater; Sharon Mates; Dean F Wong
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

Review 8.  Are second generation antipsychotics a distinct class?

Authors:  Caroline Bonham; Christopher Abbott
Journal:  J Psychiatr Pract       Date:  2008-07       Impact factor: 1.325

9.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

10.  Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.

Authors:  Shoji Tanaka
Journal:  BMC Psychiatry       Date:  2010-02-27       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.